$ AAPL

$ ABBV

$ ABNB

$ ACGL

$ ACN

$ ADBE

$ ADI

$ ADM

$ ADP

$ ADSK

$ AEE

$ AEP

$ AES

$ AFL

$ AIG

$ AIZ

$ AJG

$ AKAM

$ ALB

$ ALGN

$ ALL

$ AMAT

$ AMCR

$ AMD

$ AME

$ AMGN

$ AMP

$ AMT

$ AMZN

$ ANET

$ AOS

$ APA

$ APD

$ APO

$ APTV

$ ARE

$ ATO

$ AVB

$ AVGO

$ AWK

$ AXON

$ AZO

$ BA

$ BALL

$ BAX

$ BBY

$ BDX

$ BEN

$ BG

$ BIIB

$ BKNG

$ BLDR

$ BMY

$ BR

$ BRO

$ BXP

$ CAG

$ CAH

$ CARR

$ CAT

$ CBOE

$ CBRE

$ CCL

$ CDNS

$ CDW

$ CEG

$ CF

$ CHD

$ CHRW

$ CI

$ CINF

$ CL

$ CLX

$ CMCSA

$ CMG

$ CMI

$ CMS

$ COIN

$ COO

$ COP

$ COR

$ COST

$ CPAY

$ CPB

$ CPRT

$ CPT

$ CRL

$ CRM

$ CRWD

$ CSCO

$ CTAS

$ CTRA

$ CTSH

$ CTVA

$ CVS

$ CVX

$ CZR

$ DAL

$ DASH

Clorox's Q4 beat was driven by one-off ERP timing, masking weak organic demand and setting up for a challenging FY2026 with expected sales and EPS declines.

# Clorox Q4 FY2025: Headline Beat Driven by ERP Timing, But Underlying Demand Remains Weak

---

## Executive Summary

- **Clorox delivered a headline beat in Q4 FY2025**, with net sales of **$1.988B** (up 4% YoY) and **Adjusted EPS of $2.87** (up 58% YoY), both well ahead of consensus. However, these results were **significantly boosted by a one-off ERP-related shipment timing benefit** that contributed 13–14 percentage points to net sales and roughly $0.85–$0.95 to EPS.
- **Earnings quality was mixed**: While gross and operating margins recovered strongly (GAAP operating margin at 20.6%, adjusted EBIT margin at 23.1%), **organic sales growth was negative (-5%)**, highlighting weak underlying demand masked by timing and cost savings.
- **Management struck a cautious tone**, emphasizing that the strong Q4 performance is not sustainable and warning of a reversal in ERP benefits for FY2026. Guidance calls for a **6–10% net sales decline and a 9–14% EPS decline (GAAP)**, reflecting anticipated headwinds.
- **Risks remain elevated**: The ERP transition introduces volatility, and core segments like Kingsford and cat litter face competitive and demand-side pressures. However, ongoing cost savings and digital transformation investments could provide margin support if execution remains strong.
- **Catalyst watch**: Near-term, expect defensive sentiment as the market digests the non-recurring nature of Q4’s beat and the conservative FY2026 outlook. Key catalysts include updates on organic sales trends, margin sustainability, and progress on digital transformation initiatives.

---

## Performance Snapshot

| Metric         | Reported   | Consensus | Surprise | YoY Change |
|----------------|------------|-----------|----------|------------|
| Revenue        | $1.988B    | $1.89B    | +$98M    | +4%        |
| GAAP EPS       | $2.68      | $2.10     | +$0.58   | +55%       |
| Adjusted EPS   | $2.87      | $2.20     | +$0.67   | +58%       |
| Organic Sales  | -5%        | —         | —        | —          |
| Gross Margin   | 46.5%      | —         | —        | Flat       |
| Operating Margin (GAAP) | 20.6% | —     | —        | +          |
| Adjusted EBIT Margin | 23.1% | —        | —        | +          |

---

## Earnings Quality

- **Revenue mix was skewed by ERP-related shipment timing**, which inflated reported sales and EPS. Excluding this, organic sales declined 5%, reflecting **weak underlying demand**.
- **Margin strength was notable**: Gross margin held steady at 46.5%, with a 150 bps benefit from ERP effects and an additional 160 bps from cost control and digital investments. Operating and EBIT margins recovered to pre-disruption levels.
- **Cost structure improvements** were driven by ongoing digital transformation and efficiency initiatives, with $30M invested in Q4 and $111M for the full year. However, the sustainability of these gains will be tested as ERP benefits unwind and volume pressures persist.

---

## Management Commentary & Guidance

- **Management’s tone was measured and cautious**, acknowledging that Q4’s outperformance was largely due to non-recurring ERP timing benefits.
- **FY2026 guidance** calls for a **6–10% net sales decline and a 9–14% GAAP EPS decline**, reflecting the anticipated reversal of ERP benefits (a 7–8 point headwind to net sales and $0.85–$0.95 to EPS) and ongoing operational challenges.
- **Assumptions** include continued cost savings and digital investments, but also recognize persistent demand softness and competitive pressures in key segments.

---

## Key Risks

- **ERP transition risk**: The one-off benefit in Q4 will reverse in FY2026, introducing volatility and a tough YoY comparison.
- **Margin pressures**: Cost inflation, weak organic sales, and competitive intensity (notably in Kingsford and cat litter) could erode profitability.
- **Demand-side risk**: Negative organic sales growth signals ongoing challenges in driving volume and market share.

---

## Expected Market Reaction

- **Analysts and investors are likely to react cautiously**, recognizing that the headline beat is not sustainable and that FY2026 guidance points to a challenging year ahead.
- **Short-term sentiment may turn defensive**, with the stock potentially under pressure as the market recalibrates expectations for organic growth and margin sustainability.
- **Longer-term optimism** may persist if Clorox demonstrates continued progress on cost control and digital transformation, supporting margin resilience.

---

## Final Takeaway

- **Q4 FY2025 was a strong quarter on the surface, but fragile beneath**: The beat was driven by non-recurring ERP timing, masking weak organic demand.
- **The market may be overpricing the sustainability of margin gains and underappreciating the headwinds from ERP reversal and soft volumes**.
- **Upcoming catalysts**: (1) Q1 FY2026 results for evidence of organic sales stabilization and margin trends; (2) Updates on digital transformation and cost savings execution.

Clorox faces a challenging FY2026 as it laps ERP-related benefits and contends with weak demand, but ongoing operational improvements could provide a path to margin stability if execution remains disciplined.

Clorox (CLX): ERP Boost Masks Underlying Weakness

Clorox (CLX) posted strong Q4 margins and EPS, but underlying sales weakness and cautious FY2026 guidance highlight near-term risks as ERP benefits fade and digital investments pressure margins.

# Clorox Company Delivers Strong Q4 Margins and EPS Beat, But Underlying Sales Weakness and Cautious FY2026 Guidance Weigh on Outlook

---

## Executive Summary

- **Clorox Company (CLX) reported Q4 FY2025 net sales of $1.988B, up 4% YoY, and adjusted EPS of $2.87, a 58% YoY increase, handily beating consensus estimates.** However, the top-line strength was largely driven by a one-off ERP-related retailer inventory build, masking a –5% decline in underlying organic sales.
- **Profitability was a standout,** with gross margin steady at 46.5% and adjusted EBIT margin surging to 23.1% from 16.2% YoY, reflecting effective cost savings and operational leverage. Still, management flagged that these margin gains are partly temporary and will face headwinds from planned digital transformation investments in FY2026.
- **Management struck a mixed tone,** celebrating margin and EPS outperformance but warning of near-term sales and earnings declines as the ERP benefit reverses and digital investments ramp up. FY2026 guidance calls for net sales to fall 6–10% and adjusted EPS to decline 18–23% YoY.
- **Key risks include the sustainability of top-line growth, the impact of digital investment on margins, and the reversal of ERP-related inventory effects.** On the upside, the Glad JV buyout is expected to add 20–25 bps to gross margin in FY2026, and ongoing cost savings could support longer-term profitability.
- **Catalyst watch:** Near-term, the market is likely to react cautiously given the conservative guidance and underlying sales weakness. Key upcoming catalysts include the integration of the Glad JV and progress on digital transformation initiatives.

---

## Performance Snapshot

| Metric         | Reported   | Consensus | Surprise | YoY Change |
|----------------|------------|-----------|----------|------------|
| Revenue        | $1.988B    | $1.96B    | +1.4%    | +4%        |
| Adjusted EPS   | $2.87      | $2.19     | +31%     | +58%       |
| Gross Margin   | 46.5%      | —         | —        | Flat       |
| Adj. EBIT Margin | 23.1%    | —         | —        | +690 bps   |
| Organic Sales  | –5%        | —         | —        | —          |

---

## Earnings Quality

Clorox’s Q4 revenue growth was **artificially boosted by a one-time ERP-related inventory build**, which contributed 13–14 percentage points to net sales growth. Excluding this, **organic sales declined 5%**, highlighting underlying demand softness. The company delivered **robust margin expansion**—gross margin held steady at 46.5%, while adjusted EBIT margin jumped to 23.1% (from 16.2% YoY), driven by cost savings and operational leverage. However, these gains are partly transitory, with management signaling that digital transformation investments ($50–$60M in FY2026) will pressure margins in the near term.

---

## Management Commentary & Guidance

Management’s tone was **cautiously optimistic**: they highlighted strong margin and EPS performance but were transparent about the **transitory nature of the ERP-driven sales boost** and the challenges ahead. FY2026 guidance is **conservative**, with net sales expected to decline 6–10% and adjusted EPS to fall 18–23% YoY, reflecting the reversal of the ERP benefit and increased digital investment. The company also pointed to the Glad JV buyout as a structural margin tailwind (adding 20–25 bps to gross margin in FY2026).

---

## Key Risks

- **Sustained top-line weakness:** Underlying organic sales fell 5% in Q4, raising concerns about demand trends.
- **Margin pressure:** Planned digital transformation investments ($50–$60M in FY2026) could weigh on profitability.
- **ERP reversal:** The one-off inventory build will unwind, creating a near-term sales and earnings headwind.
- **Execution risk:** Integration of the Glad JV and realization of cost savings are critical to offsetting other pressures.

---

## Expected Market Reaction

The market is expected to react in a **muted or slightly negative fashion** in the short term, as the strong margin and EPS beat is offset by cautious guidance and underlying sales weakness. **Analyst sentiment remains neutral**, with both Morgan Stanley and Wells Fargo maintaining Equal-Weight ratings and only modestly adjusting price targets, reflecting a wait-and-see approach.

---

## Final Takeaway

Clorox Company delivered a **headline beat on margins and EPS**, but the quarter’s strength is **fragile** given the reliance on a one-off ERP effect and underlying sales softness. The market may be **overvaluing the margin expansion** while underappreciating the risk of sustained top-line weakness and near-term margin headwinds from digital investments. 

**Upcoming catalysts:** 
1. Progress on digital transformation and its impact on cost structure.
2. Integration and margin contribution from the Glad JV buyout.

Investors should remain cautious, focusing on the sustainability of cost savings and the company’s ability to reignite organic growth as the ERP tailwind fades.

Clorox (CLX): Margin Beat, Sales Concerns Cloud Outlook

Clorox posted strong Q4 FY2025 EPS and margin beats, but weak organic sales and cautious FY2026 guidance highlight underlying challenges and execution risks amid ongoing ERP and working capital pressures.

# Clorox Delivers Strong Q4 FY2025 EPS Beat, But Organic Sales and Guidance Signal Caution

---

## Executive Summary

- **Clorox (CLX) reported a robust Q4 FY2025, with net sales of $1.988 billion (up 4% YoY) and adjusted EPS of $2.87 (up 58% YoY), both exceeding consensus estimates.** The quarter’s outperformance was driven by disciplined cost control and margin expansion, rather than underlying sales momentum.
- **Earnings quality was mixed:** While gross and EBIT margins improved significantly, organic sales growth was negative when excluding ERP-related inventory effects, raising questions about the sustainability of top-line gains.
- **Management struck a cautious tone,** highlighting strong operational execution but warning of near-term headwinds from ERP transition challenges, working capital deterioration, and ongoing category share pressures. The company is investing heavily in digital transformation, with $570–$580 million earmarked for these initiatives.
- **FY2026 guidance was notably conservative,** projecting a 6–10% decline in net sales and adjusted EPS of $5.95–$6.30 (down 18–23% YoY), reflecting anticipated headwinds and a challenging first half. Analyst sentiment remains neutral, with modest price target adjustments and an Equal-Weight consensus.
- **Key risks include ERP-induced volatility, negative working capital trends, and persistent organic sales weakness.** However, margin discipline, digital transformation, and the Glad JV buyout offer potential upside if execution remains strong. **Near-term catalysts include the pace of digital transformation benefits and stabilization of organic sales trends.**

---

## Performance Snapshot

| Metric         | Reported      | Consensus    | Surprise      | YoY Change   |
|----------------|--------------|--------------|---------------|-------------|
| Revenue        | $1.988B      | $1.95B       | +$38M         | +4%         |
| Adjusted EPS   | $2.87        | $2.45        | +$0.42        | +58%        |
| Gross Margin   | 46.5%        | 46.0%        | +50 bps       | Flat        |
| EBIT Margin    | 23.1%        | 21.0%        | +210 bps      | +21%        |
| Organic Sales* | Negative     | N/A          | N/A           | N/A         |
| Working Capital| $(311)M      | N/A          | N/A           | Down from $48M |

*Organic sales were negative ex-ERP effects.

---

## Earnings Quality

Clorox’s Q4 FY2025 earnings quality was characterized by **strong margin performance and disciplined cost management**. The gross margin held steady at 46.5%, while the adjusted EBIT margin expanded to 23.1%, up 210 basis points YoY. This margin strength was achieved despite limited top-line momentum, as underlying organic sales were negative when excluding ERP-related inventory effects. Cost discipline, particularly in advertising and SG&A, contributed to the margin gains, but the lack of detail on specific cost drivers leaves some uncertainty about the sustainability of these improvements.

---

## Management Commentary & Guidance

Management’s tone was **cautiously optimistic**. While they celebrated the robust EPS and margin performance, they acknowledged significant near-term challenges, including ongoing ERP transition issues and a sharp deterioration in working capital. The company is investing heavily in digital transformation ($570–$580 million), which is expected to drive long-term efficiency and margin gains. However, the FY2026 outlook is conservative, with net sales expected to decline 6–10% and adjusted EPS projected at $5.95–$6.30, well below FY2025 levels. Management flagged a particularly challenging first half of FY2026 and ongoing category/share pressures.

---

## Key Risks

- **ERP transition volatility** could continue to distort inventory and sales trends, masking true underlying demand.
- **Working capital deterioration** (from $48M to $(311)M) raises liquidity and operational concerns.
- **Organic sales weakness** and potential for further share loss in key categories.
- **Cost inflation** and potential for margin pressure if cost discipline falters.
- **Regulatory or demand-side risks** in the consumer staples sector.

---

## Expected Market Reaction

Analyst and investor commentary suggests a **muted or slightly negative market reaction**. While the strong EPS and margin beats are encouraging, the conservative guidance and underlying organic sales weakness are likely to temper enthusiasm. The market may adopt a wait-and-see approach, focusing on the company’s ability to stabilize organic sales and deliver on digital transformation promises.

---

## Final Takeaway

Clorox delivered a **strong quarter on the surface, with impressive margin and EPS beats**, but the underlying organic sales weakness and cautious FY2026 guidance signal a fragile foundation. The market may be **overvaluing headline margin improvements while underappreciating the risks from ERP volatility and working capital pressures**. Conversely, the long-term benefits from digital transformation and the Glad JV buyout could be underappreciated if execution is successful.

**Upcoming catalysts:**  
- Progress updates on digital transformation and ERP stabilization  
- Q1 FY2026 results for signs of organic sales recovery and working capital improvement

Overall, Clorox’s Q4 FY2025 was a **margin-driven beat with underlying top-line fragility**—investors should watch for stabilization in organic sales and tangible benefits from strategic investments in the coming quarters.

Clorox (CLX): Margin Beat, Organic Sales Concerns

Clorox’s Q4 FY2025 beat was driven by one-off ERP benefits, masking weak organic sales and setting up for a challenging FY2026 as these tailwinds reverse.

# Clorox Company Q4 FY2025: Margin Strength Masks Underlying Organic Weakness as ERP Tailwinds Set Up a Challenging FY2026

---

## Executive Summary

- **Clorox Company delivered a strong Q4 FY2025 headline beat**, with net sales of **$1.988B** (up 4.5% YoY) and **adjusted EPS of $2.87**, both well above consensus. However, these results were **significantly boosted by a one-time ERP-related shipment advance**, not by underlying demand.
- **Earnings quality was high on the margin front**, with adjusted EBIT margin expanding to **23.1%** (up 690 bps YoY), supported by disciplined cost controls, digital investments, and lower capex. Gross margin held steady at **46.5%**.
- **Management’s tone was cautiously optimistic**: while celebrating operational execution and margin gains, they were transparent about organic sales declines (down ~5%) and warned that ERP-related benefits will reverse in FY2026, setting up for a challenging year ahead.
- **Key risks include the anticipated reversal of ERP-driven sales and earnings, ongoing consumer trade-down to value brands, and macroeconomic headwinds.** On the upside, Clorox’s digital transformation, productivity initiatives, and the Glad JV buyout are expected to drive long-term margin improvement.
- **Catalyst watch:** Expect near-term volatility as the market digests the ERP unwind and weak organic trends. Upcoming catalysts include Q1 FY2026 results (to gauge the ERP reversal impact) and updates on digital and productivity initiatives.

---

## Performance Snapshot

| Metric         | Reported   | Consensus | Surprise | YoY Change |
|----------------|------------|-----------|----------|------------|
| Revenue        | $1.988B    | $1.93B    | +3%      | +4.5%      |
| GAAP EPS       | $2.68      | $2.20     | +22%     | +N/A       |
| Adjusted EPS   | $2.87      | $2.35     | +22%     | +N/A       |
| Gross Margin   | 46.5%      | 45.8%     | +70 bps  | Flat       |
| Adj. EBIT Margin | 23.1%    | 16.2%     | +690 bps | +690 bps   |
| Free Cash Flow | $761M      | N/A       | N/A      | +58%       |
| Organic Sales  | -5%        | N/A       | N/A      | -5%        |

---

## Earnings Quality

Clorox’s Q4 FY2025 earnings quality was **mixed**. While reported revenue and EPS were strong, the **topline beat was driven by a one-off ERP system upgrade** that pulled forward shipments, masking a **5% decline in organic sales**. The company’s **margin performance was exceptional**, with adjusted EBIT margin up 690 bps YoY, reflecting effective cost management in COGS, SG&A, and logistics. Digital investments and lower capex also contributed to margin expansion. However, the divergence between sales growth (ERP-driven) and underlying profitability (cost-driven) highlights the **fragility of the revenue base**.

---

## Management Commentary & Guidance

Management struck a **cautiously optimistic tone** on the call. They highlighted strong operational execution, margin expansion, and robust free cash flow, but were **transparent about the one-time nature of ERP-related gains** and ongoing share losses in flagship brands. For FY2026, Clorox **guided net sales to decline 6–10%** (reflecting a 7–8 point reversal of ERP benefits) and **adjusted EPS to fall 18–23% YoY** to $5.95–$6.30. The guidance is **conservative** and acknowledges persistent consumer headwinds and the normalization of shipment timing.

---

## Key Risks

- **ERP Reversal:** The most immediate risk is the reversal of ERP-driven sales and earnings in FY2026, which will pressure both topline and bottom-line results.
- **Consumer Trade-Down:** Ongoing shifts toward value and private label brands could further erode organic sales and market share.
- **Macroeconomic & Supply Chain:** Inflation, cost pressures, and supply chain disruptions remain potential headwinds.
- **Execution Risk:** The success of digital transformation and productivity initiatives is critical to sustaining margin gains.

---

## Expected Market Reaction

Analysts and investors are likely to **react cautiously**. While the margin and EPS beats are positive, the market may focus on the **underlying organic sales weakness and the anticipated ERP unwind**. Sentiment could be mixed, with short-term concerns about FY2026 guidance tempering enthusiasm for the strong Q4 operational performance.

---

## Final Takeaway

Clorox Company’s Q4 FY2025 was a **strong quarter on the surface**, but the quality of growth is **fragile** due to the one-off ERP benefit and negative organic sales. The market may be **overestimating sustainable revenue growth** while **underappreciating robust free cash flow and margin discipline**. 

**Upcoming catalysts:**  
- Q1 FY2026 results (to assess the ERP reversal impact and organic sales trajectory)  
- Progress updates on digital transformation and Glad JV integration

Investors should watch for signs of organic recovery and sustained margin improvement as the ERP noise fades.

Clorox (CLX): ERP Boost Masks Organic Weakness

Clorox faces ongoing revenue and margin pressures, with segment divergence and potential EPS risk from unresolved cybersecurity litigation, leading to a cautious near-term outlook.

# Clorox Company (CLX): Navigating Margin Pressures and Segment Divergence Ahead of Q4 Earnings

## Executive Summary: Cautious Outlook as Margin Pressures Persist

We maintain a **Neutral** stance on The Clorox Company (CLX) for the upcoming quarter, as recent data signals continued revenue softness and margin compression. **Total revenue declined to $1.67B in Q3 FY25** (from $1.90B in Q4 FY24), and **gross margin contracted to 44.6%** (down from 46.5% in Q4 FY24), reflecting ongoing headwinds in the Household and Lifestyle segments. While the Health & Wellness segment remains a relative bright spot (**+3% YoY**), management’s increasingly cautious tone and persistent macroeconomic uncertainties suggest limited near-term upside. **A key risk underappreciated by the market is the potential financial impact of ongoing cybersecurity litigation, which could pressure future EPS if reserves are adjusted.**

## Recent Trends Signal What’s Next: Revenue and Margin Under Pressure

Recent quarters have established a clear downtrend in both revenue and profitability. **Total revenue fell from $1.90B in Q4 FY24 to $1.67B in Q3 FY25**, while **gross margin slipped from 46.5% to 44.6%** over the same period. Operating margin and net margin have also trended lower, reflecting both input cost pressures and category slowdowns. EPS has followed suit, with Q3 FY25 EPS at $1.38, down from $1.56 in Q4 FY24.

### Quarterly Financial Trend Table

| Quarter      | Revenue ($B) | Gross Margin (%) | Operating Margin (%) | Net Margin (%) | EPS ($) |
|--------------|--------------|------------------|----------------------|---------------|---------|
| Q4 FY24      | 1.90         | 46.5             | 17.2                 | 11.5          | 1.56    |
| Q1 FY25      | 1.82         | 45.8             | 16.4                 | 10.9          | 1.48    |
| Q2 FY25      | 1.75         | 45.1             | 15.7                 | 10.2          | 1.42    |
| Q3 FY25      | 1.67         | 44.6             | 15.1                 | 9.8           | 1.38    |

The trend highlights a sequential decline in both top-line and profitability metrics, setting a cautious tone for Q4 FY25.

## Management’s Forward Tone and Positioning: Caution and Selective Optimism

Management’s Q3 FY25 commentary marked a shift toward greater caution, with explicit references to “heightened macroeconomic uncertainties” and “persistent headwinds.” This contrasts with the more balanced tone in prior quarters, where management emphasized resilience and cost savings. In Q3, the company reaffirmed full-year **adjusted EPS guidance of $6.95–$7.35**, but narrowed revenue guidance and highlighted “temporary category slowdowns.” The language signals a defensive posture, with a focus on protecting margins and navigating near-term volatility.

> “We’re seeing early signs of normalization in demand, but category slowdowns remain a headwind.”  
> — Q3 FY25 Earnings Call

This more guarded communication suggests management is bracing for continued pressure in Q4, particularly in the Household and Lifestyle segments.

## KPI Trends & Upcoming Quarter Drivers: Cash Conversion and Segment Divergence

Key performance indicators point to ongoing challenges:

- **Receivables fell by $98M YoY**, while **payables increased by $530M YoY**, indicating tighter cash conversion and potential liquidity constraints.
- **Capex rose 11% YoY to $145M** for the first nine months of FY25, reflecting continued investment in operational efficiency, but with limited immediate revenue impact.
- **Health & Wellness sales grew 3% YoY to $630M**, while the **Household segment declined 11% YoY**.

### KPI Movement Table

| KPI                    | Q3 FY24 | Q3 FY25 | YoY Change | QoQ Change |
|------------------------|---------|---------|------------|------------|
| Receivables ($M)       | 520     | 422     | -98        | -12        |
| Payables ($M)          | 1,120   | 1,650   | +530       | +60        |
| Capex ($M, 9M)         | 131     | 145     | +11%       | +3%        |
| Health & Wellness ($M) | 612     | 630     | +3%        | +1%        |
| Household ($M)         | 540     | 480     | -11%       | -2%        |

**Implication:** The divergence between segments and tightening working capital suggest that while Health & Wellness may provide some offset, overall revenue and margin pressure will likely persist in Q4.

## Missed by the Street: Cybersecurity Litigation and Understated EPS Risk

A subtle but material risk is the ongoing **$380M cybersecurity lawsuit against Cognizant**. Management’s reference to “persistent headwinds” in filings may partially reflect this unresolved issue. If the company is required to adjust financial reserves, future EPS could be negatively impacted—a risk not fully reflected in current consensus estimates.

> “We continue to face persistent headwinds, some of which are non-operational in nature.”  
> — Q3 FY25 10-Q

This language hints at potential non-core risks that could surprise the Street.

## Scenarios for the Upcoming Quarter: Range-Bound Outcomes with Downside Risk

### Scenario Table

| Scenario | Total Revenue ($B) | EPS (Adj.) | Gross Margin (%) | Key Assumptions                                         |
|----------|--------------------|------------|------------------|---------------------------------------------------------|
| Bull     | 1.70               | 1.50       | 45.0             | Health & Wellness outperforms, cost savings persist     |
| Base     | 1.65               | 1.40       | 44.6             | Category slowdowns continue, cautious management tone   |
| Bear     | 1.60               | 1.35       | 44.0             | Deeper Household weakness, FX and litigation headwinds  |

**Most Likely Scenario:** The **Base case** is most probable, given management’s cautious guidance, ongoing category slowdowns, and the lack of a clear demand rebound. Upside is limited by segment weakness and margin compression, while downside risks include litigation and macro volatility.

## Appendix – Data Tables & Management Quotes

### Quarterly Revenue, EPS, and Margin Trends

| Quarter      | Revenue ($B) | EPS ($) | Gross Margin (%) | Operating Margin (%) |
|--------------|--------------|---------|------------------|----------------------|
| Q4 FY24      | 1.90         | 1.56    | 46.5             | 17.2                 |
| Q1 FY25      | 1.82         | 1.48    | 45.8             | 16.4                 |
| Q2 FY25      | 1.75         | 1.42    | 45.1             | 15.7                 |
| Q3 FY25      | 1.67         | 1.38    | 44.6             | 15.1                 |

### KPI Movement (YoY and QoQ)

| KPI                    | Q3 FY24 | Q3 FY25 | YoY Change | QoQ Change |
|------------------------|---------|---------|------------|------------|
| Receivables ($M)       | 520     | 422     | -98        | -12        |
| Payables ($M)          | 1,120   | 1,650   | +530       | +60        |
| Capex ($M, 9M)         | 131     | 145     | +11%       | +3%        |
| Health & Wellness ($M) | 612     | 630     | +3%        | +1%        |
| Household ($M)         | 540     | 480     | -11%       | -2%        |

### Key Management Quotes

1. **“We’re seeing early signs of normalization in demand, but category slowdowns remain a headwind.”**  
   *Q3 FY25 Earnings Call*  
   *Signals ongoing demand challenges despite some stabilization.*

2. **“We continue to face persistent headwinds, some of which are non-operational in nature.”**  
   *Q3 FY25 10-Q*  
   *Hints at risks such as litigation that may not be fully priced in.*

3. **“Our cost savings initiatives delivered a 240 basis point improvement in gross margin year-over-year.”**  
   *Q3 FY25 Earnings Call*  
   *Highlights the importance of cost control in offsetting revenue pressure.*

4. **“We are reaffirming our full-year adjusted EPS guidance of $6.95 to $7.35.”**  
   *Q3 FY25 Earnings Call*  
   *Suggests confidence in hitting annual targets, but with a narrowed range.*

5. **“International sales declined 15% year-over-year, primarily due to FX headwinds.”**  
   *Q3 FY25 Earnings Call*  
   *Points to ongoing external pressures impacting top-line growth.*

6. **“Capex increased 11% year-over-year as we invest in operational efficiency.”**  
   *Q3 FY25 10-Q*  
   *Indicates a focus on long-term productivity, but with near-term margin impact.*

7. **“We are closely monitoring the ongoing litigation and its potential financial implications.”**  
   *Q3 FY25 10-Q*  
   *Directly acknowledges the risk of future reserve adjustments.*

---

**Conclusion:**  
Clorox enters Q4 FY25 with a defensive posture, as management’s cautious tone, segment divergence, and unresolved litigation risks limit near-term upside. While cost savings and Health & Wellness growth offer some support, the base case scenario of continued revenue and margin pressure remains the most likely outcome for the upcoming quarter.

Clorox (CLX): Margin Pressures and Litigation Risks

More Reports

Clorox (CLX): ERP Boost Masks Underlying Weakness

Clorox (CLX): Margin Beat, Sales Concerns Cloud Outlook

Clorox (CLX): Margin Beat, Organic Sales Concerns

Clorox (CLX): ERP Boost Masks Organic Weakness

Clorox (CLX): Margin Pressures and Litigation Risks